Cheung Lily 4

What Happened
Lily Cheung, Chief Human Resource Officer of Pliant Therapeutics (PLRX), disposed of 7,534 shares on January 20, 2026 in a sale that generated approximately $9,644 (weighted average price $1.28 per share). The sale was executed as part of a nondiscretionary transaction to satisfy withholding tax obligations associated with the vesting of previously granted restricted stock units.

Key Details

• Transaction date: January 20, 2026 (Form 4 filed January 22, 2026 — appears timely within the two-business-day reporting window).
• Reported sale: 7,534 shares at a weighted average price of $1.28; total proceeds ≈ $9,644.
• Price range: broker executed shares for the employee group at prices between $1.245 and $1.33 (Jan 20–22, 2026); the $1.28 figure is the Reporting Person’s weighted-average share price.
• Footnote: Sale was a nondiscretionary 10b5-1 plan transaction to cover tax withholding on vested RSUs; the filing notes the sale was part of a group of employees and offers to provide detailed per-price breakdown on request.
• Shares owned after the transaction: Not specified in the provided filing.
• Additional note: Filing also references 1,956 shares acquired under an Employee Stock Purchase Plan (ESP P) (footnote F2).

Context
This sale was executed to satisfy tax-withholding obligations arising from RSU vesting (routine administrative sale) rather than an open discretionary sale that would necessarily indicate a change in sentiment. For retail investors, purchases tend to carry more informational weight than routine withholding sales; this filing should be read in that administrative context.